Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,821 to 3,840 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants With All Myocardial Infarction (MI) | 159 of 1,187 69 of 612 | 2.1 points -1.2 to 5.2 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Cardiac Death/TV-MI/ID-TLR (TLF) | 220 of 1,187 98 of 612 | 2.5 points -1.2 to 6.1 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR) | 108 of 1,187 40 of 612 | 2.6 points -0.1 to 5.0 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | 245 of 1,187 113 of 612 | 2.2 points -1.8 to 5.9 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Death/All MI | 230 of 1,187 101 of 612 | 2.9 points -0.9 to 6.5 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Intervention vs Baseline Period: Percentage of Cases Who Received Excessive Post-procedural Antimicrobials | 216 of 525 644 of 1,272 | -9.5 points -14.4 to -4.4 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline Period: Percentage of Cases Who Received a Late Antimicrobial Prescription | 83 of 525 169 of 1,272 | 2.5 points -1.0 to 6.3 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline Period: Percentage of Cases Who Underwent Clostridioides Difficile Testing | 1 of 525 6 of 1,272 | -0.3 points -0.9 to 0.6 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline Period: Percentage of Cases Who Died (Mortality) | 4 of 525 4 of 1,272 | 0.4 points -0.2 to 1.6 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline: deaths from any cause | 4 of 525 4 of 1,272 | 0.4 points -0.2 to 1.6 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline Period: Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic | 113 of 525 186 of 1,272 | 6.9 points 3.0 to 11.0 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Intervention vs Baseline: serious adverse events | 113 of 525 186 of 1,272 | 6.9 points 3.0 to 11.0 | 1,797 | NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 180 Days Post Vaccination | 12 of 1,198 6 of 598 | -0.0 points -1.2 to 0.9 | 1,796 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting New Onset Chronic Diseases From Administration of Investigational Product Through 180 Days Post Vaccination | 11 of 1,198 4 of 598 | 0.2 points -0.9 to 1.1 | 1,796 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Participants Reporting Any Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination | 210 of 1,198 118 of 598 | -2.2 points -6.2 to 1.5 | 1,796 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination | 2 of 1,198 2 of 598 | -0.2 points -1.1 to 0.3 | 1,796 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs All FluMist: serious adverse events | 12 of 1,198 6 of 598 | -0.0 points -1.2 to 0.9 | 1,796 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV-BFS (MEDI8662) vs All FluMist: serious adverse events | 15 of 1,198 2 of 596 | 0.9 points -0.1 to 1.8 | 1,794 | NCT00952705 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age |
| Everolimus vs Placebo: deaths from any cause | 112 of 896 119 of 896 | -0.8 points -3.9 to 2.3 | 1,792 | NCT01674140 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
| Arm 1 vs Arm 2: Secondary Endpoint | 283 of 899 312 of 892 | -3.5 points -7.8 to 0.9 | 1,791 | NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=192"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=192
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01751906-a83e4582",
"title": "Absorb BVS vs XIENCE: Number of Participants With All Myocardial Infarction (MI)",
"summary": "159 of 1187 against 69 of 612; risk difference 2.1 points, 95% interval -1.2 to 5.2; NCT01751906, ABSORB III Randomized Controlled Trial (RCT)",
"record": "/library/comparisons/NCT01751906-a83e4582",
"nct_id": "NCT01751906",
"kind": "outcome",
"participants": 1799,
"risk_difference": {
"value": 0.021206039281761555,
"lower": -0.011780932197695972,
"upper": 0.05181963144111174
},
"group_1": "159 of 1,187",
"group_2": "69 of 612",
"difference": "2.1 points",
"interval": "-1.2 to 5.2",
"trial_title": "ABSORB III Randomized Controlled Trial (RCT)"
},
{
"id": "NCT01751906-befd7054",
"title": "Absorb BVS vs XIENCE: Number of Cardiac Death/TV-MI/ID-TLR (TLF)",
"summary": "220 of 1187 against 98 of 612; risk difference 2.5 points, 95% interval -1.2 to 6.1; NCT01751906, ABSORB III Randomized Controlled Trial (RCT)",
"record": "/library/comparisons/NCT01751906-befd7054",
"nct_id": "NCT01751906",
"kind": "outcome",
"participants": 1799,
"risk_difference": {
"value": 0.025210477338927728,
"lower": -0.012410135555592915,
"upper": 0.06068918302004261
},
"group_1": "220 of 1,187",
"group_2": "98 of 612",
"difference": "2.5 points",
"interval": "-1.2 to 6.1",
"trial_title": "ABSORB III Randomized Controlled Trial (RCT)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=193",
"request_id": "r0aPmT0zuLHj1StO"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant